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Abstract
Background: Chronic systemic inflammation triggers alterations in the central nervous system
that may relate to the underlying inflammatory component reported in neurodegenerative
disorders such as multiple sclerosis and Alzheimer's disease. However, it is far from being
understood whether and how peripheral inflammation contributes to induce brain inflammatory
response in such illnesses. As part of the barriers that separate the blood from the brain, the
choroid plexus conveys inflammatory immune signals into the brain, largely through alterations in
the composition of the cerebrospinal fluid.
Results: In the present study we investigated the mouse choroid plexus gene expression profile,
using microarray analyses, in response to a repeated inflammatory stimulus induced by the
intraperitoneal administration of lipopolysaccharide every two weeks for a period of three months;
mice were sacrificed 3 and 15 days after the last lipopolysaccharide injection. The data show that
the choroid plexus displays a sustained response to the repeated inflammatory stimuli by altering
the expression profile of several genes. From a total of 24,000 probes, 369 are up-regulated and
167 are down-regulated 3 days after the last lipopolysaccharide injection, while at 15 days the
number decreases to 98 and 128, respectively. The pathways displaying the most significant changes
include those facilitating entry of cells into the cerebrospinal fluid, and those participating in the
innate immune response to infection.
Conclusion: These observations contribute to a better understanding of the brain response to
peripheral inflammation and pave the way to study their impact on the progression of several
disorders of the central nervous system in which inflammation is known to be implicated.
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Inflammation is implicated in the appearance and in the
progression of central nervous system (CNS) diseases
such as multiple sclerosis (MS) and Alzheimer's diseases
(AD), although the mechanism underlying such involve-
ment is poorly understood [1-4]. It is recognized that the
inflammation observed in the CNS of subjects with some
of these diseases may originate in the periphery [5-7], par-
ticularly when the inflammatory stimulus is persistent.
Persistence may be due to chronic inflammation or to
repeated exposure to acute inflammatory stimulus for
long periods of time. Of relevance, persistent or chronic
inflammatory signals result in excessive microglia activa-
tion and cause localized or disseminated tissue dysfunc-
tion and damage [8], ultimately resulting in accentuation
of brain pathology.
The blood-brain barriers, constituted by the endothelial
cells of the blood capillaries (blood-brain barrier-BBB)
and by the epithelial cells of the choroid plexus (CP) that
separate the blood from the cerebrospinal fluid (CSF), are
key players in the communication between the periphery
and the brain. However, most studies published to date
address the BBB interactions in response to acute periph-
eral stimulus or in the context of CNS diseases [9,10].
Recently, we showed that the blood-CSF barrier is also an
important mediator of acute peripheral inflammation
into the CNS [11]. Of notice, this response triggers molec-
ular pathways that are commonly viewed as both neuro-
protective and deleterious for the brain. Whilst the
secretion of proinflammatory cytokines into the CSF, the
decreased expression of proteins that form the epithelial
cells tight junctions and the increased expression of pro-
teins that may facilitate leukocyte trafficking into the
brain might be predicted to display deleterious effects, the
response can be also consider protective since it modu-
lates iron metabolism in a way that may prevent microor-
ganism replication in the CSF and, consequently,
dissemination within the brain [12,13]. While these
observations associate the CP response to acute peripheral
inflammation, they raise the possibility that the CP may
as well be equipped to mount a sustained response to per-
sistent peripheral inflammatory stimuli.
Importantly, scattered but relevant reports have shown
that the CP may contribute to the aetiology of CNS dis-
eases in which persistent, rather than acute inflammation,
is more likely to trigger CNS disease. In MS, and in animal
models of MS, the CP was proposed as the main route of
leukocyte entry into the brain [14,15]. In AD, it was pro-
posed that the CP participates in amyloid β peptide clear-
ance out of the brain through CSF carrier proteins (e.g.
transthyretin and apolipoprotein J) [16] that bind to
receptors (e.g. megalin) [17] in the apical membrane of
the CP epithelial cells.
These observations prompted us to investigate, using
microarray analysis, how the CP transmits immune sig-
nals into the brain in response to peripheral repetitive
inflammation. We found that the CP displays a low inten-
sity, but sustained, response to this stimulus and that the
leukocyte extravasation signalling pathway as well as
pathways that mediate the innate immune response to
infection are the most altered both 3 and 15 days after the
last LPS injection.
Results
Repeated peripheral inflammation induces alterations in 
the choroid plexus transcriptome
Mice were administered LPS once every 2 weeks for 3
months and were sacrificed 3 and 15 days after the last
LPS injection. The first time-point for sacrifice was chosen
taking into account previous reports [11] showing that 3
days after a single LPS injection few genes display an
altered expression. Comparing the gene expression profile
3 days after the last LPS injection in the present protocol
with that occurring 3 days after a single LPS administra-
tion, allowed us to identify the genes whose altered
expression is the result of the repeated rather than single
exposure to the inflammatory stimuli. Since in the present
experimental protocol LPS was administered every 2
weeks for 3 months, the analysis 15 days after the last
injection allowed us to evaluate if any changes occurring
in the gene expression profile were sustained during
repeated exposure to inflammatory stimuli.
During the duration of the experiment, the LPS dose used
did not induce any statistical significant changes in the
body weight, and the survival rate observed was of 100%.
No cage behaviour alterations were observed throughout
the experimental period.
Figure 1 shows that 3 days after the last LPS injection 536
probes have an altered expression when compared to the
saline injected animals. Since at the same time-point after
a single LPS injection [11], only 46 genes were found to
have an altered expression, this response depends on the
chronic nature of the stimuli. Moreover, a response of the
CP to the continuous peripheral stimuli is still present 15
days after the last injection, with the expression of 226
genes altered. This suggests that, contrary to what is
observed upon a single acute stimulus, repetitive LPS
injections do not allow the CP gene expression profile to
restore to its basal levels in a short period of time.
Despite the number of genes whose expression is found
altered, not many display a fold change higher than 50%
(Figure 2). In fact, as can be observed in Figure 2a, 3 days
after the last LPS injection, only 25 genes out of the 369
genes whose expression is up-regulated display a fold
change ≥ 2,0. In addition, from the 167 genes whosePage 2 of 10
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down-modulation and only 5 display a decrease as low as
1,7 fold (Figure 2a). The fold changes are even smaller
(but still statistically significant) at 15 days after the last
LPS injection (Figure 2b); only 2 genes present a fold
increase ≥ 2,0.
Table 1 lists, taking into consideration the fold change,
the 10 genes whose expression is most altered at 3 and 15
days after the last LPS injection.
To identify the genes whose altered expression was sus-
tained we looked for those that had at least a 40% change,
both at 3 and at 15 days after the last LPS stimulus. Only
7 up-regulated genes fulfil such criteria (Table 2).
Identification of altered gene pathways
We next analysed, using the Ingenuity software, the path-
ways to which the genes with altered expression belong.
From Table 3, it is clear that 15 days after the last LPS
injection only a few genes within each biological pathway
remained with altered expression. Interestingly, the sig-
nalling pathways in which a considerable number of
Chronic inflammation alters the choroid plexus gene expression profileFigure 1
Chronic inflammation alters the choroid plexus gene expression profile. Number of genes up-regulated (black) and 
down-regulated (gray) in the choroid plexus 3 and 15 days after the last LPS injection. All genes with a variation in expression 
of at least 10% (FDR 5%) were considered.
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Fold changes in gene expression. The fold change induced in most genes by the chronic stimulus is below 50%, both at 3 
days (a) and at 15 days (b) after the last LPS injection.
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BMC Neuroscience 2009, 10:135 http://www.biomedcentral.com/1471-2202/10/135genes still have altered expression 15 days after the last
injection of LPS are those related with leukocyte migra-
tion and with the complement cascade signalling.
In a previous report we characterized the kinetic gene
expression profile [from 1 h up to 3 days] in response to a
single LPS peripheral injection [11]. When the transcrip-
tome of the CP at 3 days after this acute inflammatory
stimulus is compared to that observed 3 days after the last
injection of the repeated protocol reported here, it should
be noted that: only 4 genes (rather than 12) of the acute
phase response signalling pathway, 2 genes (rather than
7) encoding for chemokines, 2 genes (rather than 5) of the
complement system and 3 (rather than 4) from the anti-
gen presentation pathway are common in both responses.
All other pathways, such as that involved in axonal guid-
Table 1: List of genes whose expression is most altered at 3 and 15 days after last LPS injection.
3 days after last LPS injection 15 days after last LPS injection
Up-regulated Up-regulated
Transcript Symbol Definition Fold change Transcript Symbol Definition Fold change
NM_011315 Saa3 Serum amyloid A 3 12,1 NM_016974.1 Dbp D site albumin promoter 
binding protein
3,3
NM_008161.1 Gpx3 Glutathione peroxidase 3 6,7 NM_145434.1 Nr1d1 Nuclear receptor 
subfamily 1 group D 
member 1
2,5
NM_017372.2 Lyzs Lysozyme 4,2 NM_008176.1 Cxcl1 Chemokine (C-X-C 
motif) ligand 1
1,9
NM_009252.1 Serpina3n Serine (or cysteine) 
proteinase inhibitor clade 
A member 3N
3,8 NM_017372.2 Lyzs Lysozyme 1,7
NM_008134.1 Glycam1 Glycosylation dependent 
cell adhesion molecule 1
3,7 NM_011328.1 Sct Secretin 1,6
NM_030707 Msr2 Macrophage scavenger 
receptor 2
3,2 NM_008161.1 Gpx3 Glutathione peroxidase 3 1,5
NM_013653.1 Ccl5 Chemokine (C-C motif) 
ligand 5
3,1 NM_175030.1 Tctex1d4 Tctex1 domain 
containing 4
1,5
NM_010185.2 Fcer1g Fc receptor IgE high affinity 
I gamma polypeptide
2,9 NM_010493.2 Icam1 Intercellular adhesion 
molecule
1,5
NM_007574.1 C1qg Complement component 1 
q subcomponent gamma 
polypeptide
2,8 NM_009778.1 C3 Complement component 
3
1,4
NM_008491.1 Lcn2 Lipocalin 2 2,7 NM_030707 Msr2 Macrophage scavenger 
receptor 2
1,4
Down-regulated Down-regulated
Transcript Symbol Definition Fold change Transcript Symbol Definition Fold change
XM_355574.1 Gnai1 Guanine nucleotide binding 
protein alpha inhibiting 1
-1,7 NM_007489.1 Arntl Aryl hydrocarbon 
receptor nuclear 
translocator-like
-2,8
NM_177644.2 Rasal2 RAS protein activator like 
2
-1,7 NM_175475.2 Cyp26b1 Cytochrome P450 family 
26 subfamily b 
polypeptide 1
-2,3
NM_018824.2 Slc23a2 Solute carrier family 23 
(nucleobase transporters) 
member 2
-1,7 NM_133903.2 Spon2 Spondin 2 extracellular 
matrix protein
-1,7
NM_011638.3 Tfrc Transferrin receptor -1,7 NM_029720.1 Creld2 Cysteine-rich with EGF-
like domains 2
-1,6
NM_178404.2 Zc3hdc6 Zinc finger CCCH type 
containing 6
-1,7 NM_175930.2 Rapgef5 Rap guanine nucleotide 
exchange factor (GEF) 5
-1,6
NM_013519.1 Foxc2 Forkhead box C2 -1,6 NM_198885.2 Scx Scleraxis -1,6
NM_148930.2 Rbm5 RNA binding motif protein 
5
-1,6 NM_175930.2 Rapgef5 Rap guanine nucleotide 
exchange factor (GEF) 5
-1,6
NM_172310.1 Tarsl2 Threonyl-tRNA 
synthetase-like 2
-1,5 NM_207261.1 Kcnk18 Potassium channel, 
subfamily K, member 18
-1,5
NM_028021.1 Myh14 Myosin, heavy polypeptide 
14
-1,5 NM_013559.1 Hsp105 Heat shock protein 105 -1,4
NM_009222.2 Snap23 Synaptosomal-associated 
protein 23
-1,5 NM_030143.2 Ddit4l DNA-damage-inducible 
transcript 4-like
-1,4Page 4 of 10
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uli are imposed, suggesting that most of these alterations
are certainly associated with the chronicity of the model
reported here.
Confirmation of array results by qRT-PCR on a set of 
relevant genes
Within each pathway, and using RNA extracted from CP
pools of an independent experiment, a number of genes
found up-regulated (Lcn2, Serpin3n, Saa3, Cxcl1, Gpx3 and
Glycam1) were chosen for qPCR analysis; this analysis
confirmed the array data. Figure 3 exemplifies the expres-
sion levels of some of these genes. Relatively to the down-
regulated genes although all the genes tested showed a
decreased expression they did not reach statistical signifi-
cance (data not shown); this could be due to the fact that
all the down-regulated genes showed only a slightly
decrease in the array (Figure 2).
Discussion and conclusion
This study shows that sustained peripheral inflammation
induced by repeated administration of LPS, every 2 weeks
for 3 months, causes an altered CP transcriptome, 3 and
15 days after the last LPS injection. We have previously
shown that an acute LPS injection triggers a rapid and
transient alteration in the CP gene expression profile, that
returns almost to basal levels after 3 days. In this study, we
show that facing repeated LPS stimuli the number of
genes whose expression is altered in the CP, compared
with the number of genes altered 3 days after an acute LPS
injection, is much higher. Another important difference is
that when compared the present study with the overall CP
response to acute LPS it is clear that the magnitude of the
fold changes is now much lower. Therefore, we can con-
clude that the chronicity of the inflammatory stimuli
alters the dynamics of the CP response. Indeed, it seems
that the repeated injection of LPS induces, in the CP, a sus-
tained transcription of specific genes encoding for mole-
cules already found transiently altered upon a single LPS
injection. These include molecules known to participate
in the host response against microorganisms, elements of
the complement and chemokines.
When the overall CP response is evaluated in terms of the
major biological pathways, 3 days after the last LPS
administration, the CP response is mainly characterized
by the increased expression of genes encoding for chem-
okines, molecules of the complement, and molecules
involved in leukocyte extravasation signalling and in the
activation of NK, T and B cells. As expected, genes belong-
ing to signalling transduction pathways are similarly
altered and are known to mediate the regulation of genes
encoding for molecules such as cytokines and molecules
of the complement. Of notice, it is well established that a
chronic inflammation can result in the inappropriate
recruitment of leukocytes and cause localized or dissemi-
nated tissue dysfunction and damage. The "leukocyte
extravasation signaling" pathway seems, in fact, the most
altered both at 3 and 15 days after the last LPS treatment.
This includes the increased expression of genes encoding
for cell adhesion molecules such as ICAM-1, glycosylation
dependent cell adhesion molecule 1 (Glycam1), mucosal
vascular addressin cell adhesion molecule 1 (Madcam1),
junction adhesion molecule 2 (Jam2) and selectin P lig-
and (Selpl); chemokines that are required for trafficking of
immune cells from the blood into tissues such as Xcl1,
Ccl7, Cxcl1, Ccl2 and interleukins such as interleukine-16
(IL-16). Of notice, we did not find IL-16 expression influ-
enced by acute inflammation [11]. IL-16 is a pleiotropic
cytokine that is a natural ligand of CD4 [18,19] and has
been identified at sites of allergic inflammation in both
the murine and the human airway epithelium [20,21].
This cytokine is known as a chemoattractant for CD4+ T
cells, monocytes, eosinophils and dendritic cells, with
preferential chemoattractant activity for the CD4+ Th1
subset [22-24]. Despite the increased expression of genes
encoding for molecules that participate in leukocyte
recruitment, no changes were observed in the expression
levels of genes that encode tight junction proteins, neither
an increase in the number of cells was observed in the CSF
Table 2: Genes whose expression is at least 40% up-regulated both at 3 and 15 days after the last LPS injection.
Genes altered 3 and 15 days after last LPS injection
Fold change
Transcript Symbol Definition 3 days 15 days
NM_008161.1 Gpx3 Glutathione peroxidase 3 6,7 1,5
NM_017372.2 Lyzs Lysozyme 4,2 1,7
NM_030707 Msr2 Macrophage scavenger receptor 2 3,2 1,4
NM_009778.1 C3 Complement component 3 2,6 1,4
NM_008176.1 Cxcl1 Chemokine (C-X-C motif) ligand 1 2,0 1,9
NM_011328.1 Sct Secretin 1,6 1,6
NM_010493.2 Icam1 Intercellular adhesion molecule 1,5 1,5Page 5 of 10
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Table 3: Clustering of the genes whose expression is altered in the choroid plexus upon repeated peripheral LPS injection.
Atered genes
3 days 15 days
Signaling pathways Toll like receptor signaling Tlr7; Mapk8; Cd14; Relb ↑ -
T cell receptor signaling Mapk8; Nfat5;Btk; Vav1; Relb ↑; Rras2; Nfatc1 ↓ Itk ↑
B cell receptor signaling Fcgr2a; Bcl2a1; Mapk8; Nfat5; Map2k7; Rac2; 
Fcgr2b; Inpp5d; Btk; Vav1; Relb ↑; Rras2; Nfatc1; 
Bcl2l1 ↓
-
SAPK JNK signaling Gpr65; Gpr24; Mapk8; Map2k7; Rac2; Sh2d2a ↑; 
Rras2; Fadd; Nfatc1; Egfr ↓
Gng11;Gpr34 ↑; Dusp8 ↓
Natural killer signaling Fcer1g; Tyrobp; Siglec7; Rac2; Klrd1; Inpp5d; Vav1; 
Hcst ↑; Rras2 ↓
Klrd1; Siglec7 ↑
NF-kB signaling Tlr7; Tnfsf13b; Mapk8; Map2k7; Relb ↑; Rras2; Egf; 
Tnfsf11; Egfr ↓ Tnfsf13b ↑
JAK/STAT signaling Stat3 ↑; Rras2 ↓ -
cAMP mediated signaling Rgs10; Grm3; Stat3 ↑; Gnai; Grk4; Cngb1; Rgs12 ↓ Adcy9; Crem ↓
Interferon signaling Isgf3g; Tap1; Ifngr2; Ifitm1; Ifitm3; Ifi205; Irf5; Ifngr2 
↑
Ifitm1 ↑
GM-CSF signaling Bcl2a1; Stat3 ↑; Rras2; Bcl2l1 ↓ -
Integrin signaling Mapk8; Actin4; Rac2 ↑; Rras2; Egfr ↓ Itgae; Itgb7 ↑
IL-10 signaling Il10ra; Tcgr2a; Mapk8; Cd14; Fcgr2b; Stat3; Relb ↑ -
IL-6 signaling Mapk8; Map2k7; Cd14; Stat3; Relb ↑; Rras2 ↓ -
IL-4 signaling Nfat5; Il2rg; Inpp5d ↑; Rras2; Nfatc1 ↓ -
IL-2 signaling Mapk8; Il2rg ↑; Rras2 ↓ -
Complement/coagulation cascade signaling C3; C1qa; C1qb; C1qg; Vwf; Serping1; C2 ↑ Serpind1; C1qg; C1qa; C3 ↓
Apoptosis signaling Casp1; Bcl2a1; Mapk8; Map2k7; Relb ↑; Rras2; 
Bcl2l1; Ecfr; Bcl2 ↓
Card14 ↑
Antigen presentation pathway B2m; H2-T23; Tap1; Psmb9 ↑ -
Acute phase response Acute phase proteins Serping1; Map2k7; C3; Mapk8;Saa3;Vwf; Stat3; Slp; 
C2; serpina3n ↑; Fn1; Rras2 ↓
C3 ↑
Leukocyte migration Leukocyte extravasation signaling Ncf2; Selpl; Mapk8; Cyba; Jam2; Actn4; Rac2; 
Mmp23; Icam1; Glycam1; Madcam1; Timp1; Btk; 
Vav1 ↑; Gnai ↓
Icam1; Itk; Cyba ↑
Extracellular matrix Timp1; Dcn; Lamb2; Fbln1; Mmp23; Tecta; Emid1 ↑; 
Fn1 ↓
Tnc; Spon2 ↓
Cytokine signaling Il16; Ccl5; Cxcl1; Ccl7; Ccl13; Xcl1; Cxcl16; Ccl2 ↑; 
Gnai1; Rras2 ↓ Cxcl1; Ccl7; Xcl1; Ccl2 ↑
Actin cytoskeleton signaling Nckap1l; Gpr65; Gpr34; Actn4; Kng1; Rac2; Cd14; 
Vav1 ↑; Rras2; Fgf7; Egf; Myh14; Fn1; Egfr ↓
Gpr34 ↑
Axonal guidance signaling Igf1; Nfat5; Rac2; Fes ↑; Gnai1; Slit2; Rras2; Rgma; 
Nfatc1; Egf; Egfr ↓
Rgmb ↑
BMC Neuroscience 2009, 10:135 http://www.biomedcentral.com/1471-2202/10/135or gross morphological changes in the CP (data not
shown). It is therefore important to further understand
whether the repeated exposure to peripheral inflamma-
tion ultimately results in the entry of immune cells into
the brain, or whether additional conditions are necessary
for such to occur.
Another interesting finding is the effect of repeated expo-
sure to LPS in the expression of genes that encode for pro-
teins involved in axonal guidance. This suggests that the
chronicity of the stimulus can induce alterations in the
normal neuronal morphology and neuronal plasticity.
One of such molecules whose gene expression is
decreased is the slit homolog 2 (Slit2). Interestingly SLIT,
a secreted protein known for its role of repulsion in axon
guidance and neuronal migration [25,26], can also inhibit
leukocyte chemotaxis induced by chemotactic factors
[26]. In addition to Slit2, the expression of the gene
encoding for the RGM domain family member A (Rgma)
is decreased in the CP after sustained inflammation.
RGMa is suggested to inhibit axon growth and synapse
formation [27]. In normal brains, RGMa expression is
detected on the perikarya of some neurons, CP, smooth
muscle, endothelial cells, oligodendrocytes, and myeli-
nated white matter fibers [28]. Interestingly, and probably
also with impact on the brain parenchyma, is the altered
expression of the gene encoding for secretin which is
increased at both time points analysed, and one of the
most altered 15 days after the last LPS injection. The secre-
tin gene is known to be expressed in several developing
brain regions namely by the CP [29]. The up regulation of
its expression may be protective for the brain parenchyma
in response to LPS since secretin deficient mice display
impaired synaptic plasticity in the CA1 area of the hippoc-
ampus [30] and given the neuroprotective role secretin
exerts on neuronal progenitor cells against ethanol-medi-
ated neurotoxicity [31]. While some proteins secreted into
the CSF may exert a function in the brain parenchyma,
others may influence the CP in itself. Among these is glu-
tathione peroxidase 3. By participating in the detoxifica-
tion of reactive oxygen spices, which are formed during an
inflammatory response, the increased expression of this
antioxidant defence enzyme [32] can be protective to the
CP epithelial cells.
Further comparison between the gene expression profiles
after exposure to a single or to repeated LPS injections,
shows that in chronicity the fold change is considerably
smaller. However, it should be noted that the expression
of some CP genes seems solely altered after the repeated
stimulation. Among these are genes encoding for proteins
of the S100 family. The S100 family of calcium-binding
proteins comprises a new group of pro-inflammatory
molecules that has been discussed in the context of MS
qRT-PCR analysis of the expression of selected genesFigure 3
qRT-PCR analysis of the expression of selected genes. Confirming the array results, the expression of Lcn2, Serpina3n, 
Saa3, Cxcl1, Gpx3, and Glycam1 (a-f) was found up-regulated by qRT-PCR.
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BMC Neuroscience 2009, 10:135 http://www.biomedcentral.com/1471-2202/10/135[33] and of AD [34]. Here we show increased levels of
S100a8 and S100a9. Another molecule exclusively
induced during the chronic treatment is the macrophage
scavenger receptor 2 (Msr2). Scavenger receptors (SRs),
initially described on macrophages as high-affinity recep-
tors for acetylated low-density lipoproteins, comprise sev-
eral receptor classes [35,36] and are expressed in various
cell types. SRs have a role in the binding and internaliza-
tion of many unrelated ligands, such as fibrillar β-amy-
loid, lipids, glycated collagen and apoptotic cells and,
therefore, are important for tissue homeostasis. The up-
regulated expression of this gene could indicate a protec-
tive role of the CP in the progression of diseases such as
AD. As referred above, clearance of amyloid β peptide out
of the brain is reported to occur through the megalin and
low-density lipoprotein receptor-related protein receptors
that are SRs [37].
The CP is composed of a vascularized stroma surrounded
by a tight layer of epithelial cells that are responsible for
producing most of the CSF. Therefore any alteration in the
CP gene expression profile may influence the CSF compo-
sition, which may then be transmitted to the brain paren-
chyma. While many of the genes whose expression we
found altered in the present study are expressed in the CP
epithelial cells [11,12], we cannot exclude the contribu-
tion of other cells of the CP stroma, such as endothelial
cells and macrophages in the observed response.
In summary, we describe here that the CP displays a sus-
tained response to a repeated inflammatory stimulus
induced in the periphery. Importantly, this response
seems to share some mechanisms previously described for
the BBB, which include the activation of adhesion and
chemoattraction signals in endothelial cells in CNS dis-
eases such as MS [9,38]. Therefore, both the blood-CSF
barrier and the BBB seem equipped to convey signals to
the brain parenchyma in response to both acute and
chronic inflammation. Future studies should further
investigate the role of the CP response in the context of
CNS disorders.
Methods
Animals and LPS injection
All experiments were conducted using 8-9 week-old
C57BL/6 male mice (Charles River, Barcelona, Spain), in
accordance with the European Community Council
Directive 86/09/EEC guidelines for the care and handling
of laboratory animals. Animals were maintained in 12 h
light/dark cycles at 22-24°C and 55% humidity and fed
with regular rodent's chow and tap water ad libitum. Ani-
mals were handled for 1 week prior to the beginning of
the experiment, in order to reduce the stress induced by
the injection. Animals were given LPS (Escherichia coli,
serotype O26:B6; Sigma, St. Louis, USA) (5 μg/g body
weight) intraperitoneally (i.p.); control animals were
injected with vehicle (0.9% NaCl) alone. Mice received
i.p. LPS or vehicle once every 2 weeks for 3 months. Ani-
mals were sacrificed 3 or 15 days after the last injection,
under anesthesia with ketamine hydrochloride (150 mg/
Kg) plus medetomidine (0.3 mg/Kg), and transcardially
perfused with cold saline. CP isolation was made under
conventional light microscopy (SZX7, Olympus, Ham-
burg, Germany) and tissue was rapidly removed, frozen in
dry ice and stored at -80°C. For the microarray experiment
three polls of CP (from 3 animals each) were prepared for
each experimental group and for each time point. For the
qRT-PCR study five pools of CP (from 3 animals each)
were used for each experimental group and for each time
point.
Microarray experimental design and data analysis
Total RNA was isolated using Trizol reagent (Invitrogen,
Calrsbad, CA, USA). Total RNA quality was assessed using
the Agilent Bioanalyzer (Santa Clara, CA, USA). After
quality assessment, 100 ng of total RNA from 3 control
pools and 3 LPS pools, for each time point, were ampli-
fied and labelled with Illumina TotalPrep RNA Amplifica-
tion Kit according to manufacturer instructions. Each pool
was composed of CP collected from 3 animals. The
labelled cRNA was then hybridized using Illumina recom-
mended protocol in a total of two Illumina Whole-
genome Mouseref-8 expression Beadchips (San Diego,
CA, USA). This mouse beadchip contains eight arrays,
each comprising a total of 24,000 well-annotated RefSeq
transcripts.
After scanning, raw data from BeadStudio software (San
Diego, CA, USA) was read into R/Bioconductor. Quality
control using inter-array Pearson correlation and cluster-
ing based on variance allowed us to ensure that there was
reproducibility between the replicates (data not shown).
Data was normalized using quantile normalization. A lin-
ear model was applied to the normalized data using
Limma package in R/Bioconductor [39]. The CP transcrip-
tome of the LPS injected animals was analysed and com-
pared with that of control animals. A contrast analysis was
applied and differentially expressed genes were selected
using a Bayesian approach with a false discovery rate
(FDR) of 5%. The differentially expressed genes were cat-
egorized using Gene Ontology from Biomart http://
www.biomart.org/ or Ingenuity tools (Redwood City, CA,
USA). Enrichment analysis was performed using the
DAVID http://david.niaid.nih.gov/david/ease.htm and
the Ingenuity software's.
Gene expression measurements by qRT-PCR
500 ng of total RNA, isolated as described above, were
amplified using a SuperScript RNA Amplification System
(Invitrogen) according to the manufacturer's instructions.Page 8 of 10
(page number not for citation purposes)
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strand cDNA using random hexamers of the superscript
first-strand synthesis system for RT-PCR (Invitrogen).
qRT-PCR analysis was used to measure the expression lev-
els of selected mRNA transcripts. Primers were designed
using the Primer3 software [40] on the basis of the respec-
tive GenBank sequences. The expression level of the refer-
ence gene hypoxanthine guanine phosphoribosyl
transferase (Hprt) (accession number from GenBank:
NM_013556) was used as internal standard for normali-
zation. All the other accession numbers and primers
sequences are available upon request. Reactions using
equal amounts of total RNA from each sample were car-
ried out on a CFX 96™ real-time system instrument (Bio-
Rad Laboratories, Hercules, CA, USA) with the QuantiTect
SYBR Green RT-PCR reagent kit (Qiagen, Hamburg, Ger-
many) according to the manufacturer's instructions. Prod-
uct fluorescence was detected at the end of the elongation
cycle. All melting curves exhibited a single sharp peak at
the expected temperature.
Statistical analysis
Values are reported as mean ± SEM. Statistical significance
was determined using the non-parametric Mann-Whitney
test, with differences considered significant at p < 0.05.
Authors' contributions
JAP, MCN, JCS, NS: conception and design, analysis and
data interpretation. FM, JCS: conception and design,
acquisition of data and analysis and interpretation of
data. GC, DHG: microarray analysis and data interpreta-
tion. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by a grant from the DANA foundation; Marques 
F is recipient of a fellowship from Fundação para a Ciência e Tecnologia 
FCT/FEDER.
References
1. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH:
Central and systemic endotoxin challenges exacerbate the
local inflammatory response and increase neuronal death
during chronic neurodegeneration.  J Neurosci 2005,
25(40):9275-9284.
2. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A: Peripheral
inflammatory biomarkers and risk of Parkinson's disease.  Am
J Epidemiol 2008, 167(1):90-95.
3. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB,
Benjamin EJ, Au R, Kiel DP, Wolf PA, et al.: Inflammatory markers
and the risk of Alzheimer disease: the Framingham Study.
Neurology 2007, 68(22):1902-1908.
4. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews
FT: Systemic LPS causes chronic neuroinflammation and
progressive neurodegeneration.  Glia 2007, 55(5):453-462.
5. Bar-Or A: The immunology of multiple sclerosis.  Semin Neurol
2008, 28(1):29-45.
6. Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, Deacon
RM, Rawlins JN, Perry VH: Systemic inflammation induces
acute behavioral and cognitive changes and accelerates neu-
rodegenerative disease.  Biol Psychiatry 2009, 65(4):304-312.
7. Teeling JL, Felton LM, Deacon RM, Cunningham C, Rawlins JN, Perry
VH: Sub-pyrogenic systemic inflammation impacts on brain
and behavior, independent of cytokines.  Brain Behav Immun
2007, 21(6):836-850.
8. Dilger RN, Johnson RW: Aging, microglial cell priming, and the
discordant central inflammatory response to signals from
the peripheral immune system.  J Leukoc Biol 2008,
84(4):932-939.
9. Engelhardt B, Ransohoff RM: The ins and outs of T-lymphocyte
trafficking to the CNS: anatomical sites and molecular
mechanisms.  Trends Immunol 2005, 26(9):485-495.
10. Engelhardt B: Regulation of immune cell entry into the central
nervous system.  Results Probl Cell Differ 2006, 43:259-280.
11. Marques F, Sousa JC, Coppola G, Falcao AM, Rodrigues AJ,
Geschwind DH, Sousa N, Correia-Neves M, Palha JA: Kinetic pro-
file of the transcriptome changes induced in the choroid
plexus by peripheral inflammation.  J Cereb Blood Flow Metab
2009, 29(5):921-932.
12. Marques F, Rodrigues AJ, Sousa JC, Coppola G, Geschwind DH, Sousa
N, Correia-Neves M, Palha JA: Lipocalin 2 is a choroid plexus
acute-phase protein.  J Cereb Blood Flow Metab 2008,
28(3):450-455.
13. Marques F, Falcao AM, Sousa JC, Coppola G, Geschwind D, Sousa N,
Correia-Neves M, Palha JA: Altered iron metabolism is part of
the choroid plexus response to peripheral inflammation.
Endocrinology 2009, 150(6):2822-2828.
14. Brown DA, Sawchenko PE: Time course and distribution of
inflammatory and neurodegenerative events suggest struc-
tural bases for the pathogenesis of experimental autoim-
mune encephalomyelitis.  J Comp Neurol 2007, 502(2):236-260.
15. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira
S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F: C-C chemok-
ine receptor 6-regulated entry of T(H)-17 cells into the CNS
through the choroid plexus is required for the initiation of
EAE.  Nat Immunol 2009, 10(5):514-523.
16. Golabek A, Marques MA, Lalowski M, Wisniewski T: Amyloid beta
binding proteins in vitro and in normal human cerebrospinal
fluid.  Neurosci Lett 1995, 191(1-2):79-82.
17. Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I: Choroid
plexus megalin is involved in neuroprotection by serum insu-
lin-like growth factor I.  J Neurosci 2005, 25(47):10884-10893.
18. Berman JS, Cruikshank WW, Center DM, Theodore AC, Beer DJ:
Chemoattractant lymphokines specific for the helper/
inducer T-lymphocyte subset.  Cell Immunol 1985, 95(1):105-112.
19. Cruikshank W, Center DM: Modulation of lymphocyte migra-
tion by human lymphokines. II. Purification of a lymphotac-
tic factor (LCF).  J Immunol 1982, 128(6):2569-2574.
20. Laberge S, Pinsonneault S, Varga EM, Till SJ, Nouri-Aria K, Jacobson
M, Cruikshank WW, Center DM, Hamid Q, Durham SR: Increased
expression of IL-16 immunoreactivity in bronchial mucosa
after segmental allergen challenge in patients with asthma.
J Allergy Clin Immunol 2000, 106(2):293-301.
21. De Bie JJ, Jonker EH, Henricks PA, Hoevenaars J, Little FF, Cruikshank
WW, Nijkamp FP, Van Oosterhout AJ: Exogenous interleukin-16
inhibits antigen-induced airway hyper-reactivity, eosi-
nophilia and Th2-type cytokine production in mice.  Clin Exp
Allergy 2002, 32(11):1651-1658.
22. Kaser A, Dunzendorfer S, Offner FA, Ryan T, Schwabegger A, Cruik-
shank WW, Wiedermann CJ, Tilg H: A role for IL-16 in the cross-
talk between dendritic cells and T cells.  J Immunol 1999,
163(6):3232-3238.
23. Lynch EA, Heijens CA, Horst NF, Center DM, Cruikshank WW:
Cutting edge: IL-16/CD4 preferentially induces Th1 cell
migration: requirement of CCR5.  J Immunol 2003,
171(10):4965-4968.
24. McFadden C, Morgan R, Rahangdale S, Green D, Yamasaki H, Center
D, Cruikshank W: Preferential migration of T regulatory cells
induced by IL-16.  J Immunol 2007, 179(10):6439-6445.
25. Li HS, Chen JH, Wu W, Fagaly T, Zhou L, Yuan W, Dupuis S, Jiang
ZH, Nash W, Gick C, et al.: Vertebrate slit, a secreted ligand for
the transmembrane protein roundabout, is a repellent for
olfactory bulb axons.  Cell 1999, 96(6):807-818.
26. Wu W, Wong K, Chen J, Jiang Z, Dupuis S, Wu JY, Rao Y: Direc-
tional guidance of neuronal migration in the olfactory sys-
tem by the protein Slit.  Nature 1999, 400(6742):331-336.Page 9 of 10
(page number not for citation purposes)
BMC Neuroscience 2009, 10:135 http://www.biomedcentral.com/1471-2202/10/135Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
27. Yoshida J, Kubo T, Yamashita T: Inhibition of branching and spine
maturation by repulsive guidance molecule in cultured cor-
tical neurons.  Biochem Biophys Res Commun 2008, 372(4):725-729.
28. Schwab JM, Monnier PP, Schluesener HJ, Conrad S, Beschorner R,
Chen L, Meyermann R, Mueller BK: Central nervous system
injury-induced repulsive guidance molecule expression in
the adult human brain.  Arch Neurol 2005, 62(10):1561-1568.
29. Siu FK, Sham MH, Chow BK: Secretin, a known gastrointestinal
peptide, is widely expressed during mouse embryonic devel-
opment.  Gene Expr Patterns 2005, 5(3):445-451.
30. Yamagata T, Urano H, Weeber EJ, Nelson DL, Nishijima I: Impaired
hippocampal synaptic function in secretin deficient mice.
Neuroscience 2008, 154(4):1417-1422.
31. Hwang DW, Givens B, Nishijima I: Ethanol-induced developmen-
tal neurodegeneration in secretin receptor-deficient mice.
Neuroreport 2009, 20(7):698-701.
32. Emerich DF, Skinner SJ, Borlongan CV, Vasconcellos AV, Thanos CG:
The choroid plexus in the rise, fall and repair of the brain.
Bioessays 2005, 27(3):262-274.
33. Giovannoni G: Multiple sclerosis cerebrospinal fluid biomark-
ers.  Dis Markers 2006, 22(4):187-196.
34. Geroldi D, Falcone C, Emanuele E: Soluble receptor for advanced
glycation end products: from disease marker to potential
therapeutic target.  Curr Med Chem 2006, 13(17):1971-1978.
35. Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC: Scav-
enger receptors in neurobiology and neuropathology: their
role on microglia and other cells of the nervous system.  Glia
2002, 40(2):195-205.
36. Murphy JE, Tedbury PR, Homer-Vanniasinkam S, Walker JH, Ponnam-
balam S: Biochemistry and cell biology of mammalian scaven-
ger receptors.  Atherosclerosis 2005, 182(1):1-15.
37. Zlokovic BV: Clearing amyloid through the blood-brain bar-
rier.  J Neurochem 2004, 89(4):807-811.
38. Bullard DC, Hu X, Schoeb TR, Collins RG, Beaudet AL, Barnum SR:
Intercellular adhesion molecule-1 expression is required on
multiple cell types for the development of experimental
autoimmune encephalomyelitis.  J Immunol 2007,
178(2):851-857.
39. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S,
Ellis B, Gautier L, Ge Y, Gentry J, et al.: Bioconductor: open soft-
ware development for computational biology and bioinfor-
matics.  Genome Biol 2004, 5(10):R80.
40. Rozen S, Skaletsky H: Primer3 on the WWW for general users
and for biologist programmers.  Methods Mol Biol 2000,
132:365-386.Page 10 of 10
(page number not for citation purposes)
